NeuroXT

What NeuroXT does

NeuroXT Inc. is a Seoul-headquartered, private AI healthcare company founded in 2022 that develops MRI-based neuroimaging biomarker software for Alzheimer's disease diagnosis and treatment suitability prediction. The company's product platform comprises two core offerings: NEXT-STAGE, an MRI-based AI that infers regional tau burden noninvasively as a cost-effective, PET-complementary solution for biopharma and academic hospital research teams; and NEXT-SCN, a world-first multimodal platform that measures in-vivo synaptic integrity to objectively verify the impact of synapse-targeted therapies. The underlying technology rests on 6 key patents transferred from Korea University Samrak Cooperation Center and AI models trained and validated against clinical data from Beth Israel Deaconess Medical Center (Harvard-affiliated) and Johns Hopkins Medical College. NeuroXT reports 90% diagnostic accuracy for Alzheimer's using its MRI-based AI analysis and positions its products as eliminating the need for costly PET scans in routine biomarker workups.

NeuroXT operates a B2B enterprise model, generating revenue through licensing its AI biomarker software to biopharma companies, academic hospitals, and research institutions. Pricing is quote-based and not publicly disclosed. The go-to-market motion is partnership-driven enterprise field sales, anchored by strategic research collaborations with leading academic medical centers (BIDMC, Johns Hopkins) and commercial biopharma engagements (Korea Eisai). The company's stated customer segments are biopharma companies running clinical trials for synapse-targeted therapies and academic hospitals performing Alzheimer's diagnosis and treatment suitability prediction.

The company is venture-backed, having raised undisclosed seed (June 2022, AJU IB and Mira Ventures), pre-seed (July 2022, Kakao Ventures), pre-A (April 2023, DAYLI Partners), pre-A (May 2023, Smilegate and Korea Investment Accelerator), and Series A (March 2025, LG, LSK Investment, Samsung Ventures, and Smilegate Investment) rounds. NeuroXT was certified as a Korean venture company and selected for the TIPS (Tech Incubator Program for Startup Korea) in July 2022. Operating geographies span Korea (HQ) and the United States (via academic research partnerships). The company has 11-50 employees and is led by CEO Seong Joon Kyung PhD.

Name

NeuroXT

Legal name

NeuroXT Inc.

Website

https://neuroxt.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroXT is a Seoul-based AI healthcare company developing MRI-based neuroimaging biomarker software (NEXT-SCN and NEXT-STAGE) for Alzheimer's disease diagnosis and treatment suitability, licensing its platform to biopharma companies and academic hospitals globally.

Ownership category

akta.pro rank

Product category

AI Neuroimaging Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

Keywords

• MRI-based AI biomarkers
• Alzheimer's diagnostics software
• Neuroimaging AI platform
• Tau burden prediction
• Synaptic integrity analysis

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. AI Imaging Biomarker Platform: NeuroXT generates revenue through licensing its AI neuroimaging biomarker technology to biopharma companies, academic hospitals, and research institutions. The platform enables biomarker-based diagnosis and treatment suitability prediction using MRI, offering a cost-effective alternative to PET scans.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

NeuroXT develops AI-powered neuroimaging software that analyzes routine MRI scans to predict amyloid and tau burden for Alzheimer's disease diagnosis and treatment suitability. The platform consists of two core products—NEXT-SCN, which measures in-vivo synaptic integrity to verify synapse-targeted therapy impact, and NEXT-STAGE, which infers regional tau burden from MRI as a cost-effective PET-complementary diagnostic tool. The software is licensed to biopharma companies and academic hospitals for clinical research and precision treatment applications.

Product overview

NeuroXT offers an AI-powered neuroimaging software platform consisting of two core products: NEXT-SCN (a multimodal platform measuring in-vivo synaptic integrity for synapse-targeted therapy verification) and NEXT-STAGE (an MRI-based solution inferring regional tau burden to enable PET-complementary diagnostics). Both products analyze routine MRI scans to predict amyloid and tau burden, eliminating the need for costly PET scans and enabling biomarker-based diagnosis and treatment suitability prediction for Alzheimer's disease.

Differentiator

Problem solved

Functional benefit

Products and services

• NEXT-SCN World-first multimodal AI platform that measures in-vivo synaptic integrity to objectively verify the impact of synapse-targeted therapies. Built for research teams in biopharma and academic hospitals conducting Alzheimer's clinical research.
• NEXT-STAGE MRI-based AI platform that infers regional tau burden from routine MRI scans, offering a noninvasive, scalable, and cost-effective PET-complementary analysis for tau burden assessment. Designed for research teams in biopharma companies and academic hospitals.

Quantifiable outcome

• 90% diagnostic accuracy for Alzheimer's using MRI-based AI analysis

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Korea EisaiminorStrategic or Co-development Partner · 7 December 2025Korea Eisai (Korean subsidiary of Japanese pharmaceutical company Eisai) partnered with NeuroXT as part of its open innovation strategy in digital healthcare. NeuroXT contributes AI technology for Alzheimer's diagnosis as part of efforts focused on dementia prevention, diagnosis, and management.
• Johns Hopkins Medical CollegecoreStrategic or Co-development Partner · 3 November 2025Strategic research partnership to validate NeuroXT's AI imaging biomarker technology using Johns Hopkins' clinical data. The collaboration aims to establish personalized treatment guidelines for Alzheimer's patients and maximize treatment effectiveness.
• Beth Israel Deaconess Medical Center (BIDMC)coreStrategic or Co-development Partner · 27 August 2024NeuroXT and BIDMC (Harvard-affiliated medical center in Boston) have an expanded research collaboration to use AI and medical imaging to understand how individual patients respond to Alzheimer's therapies. Building on a 2024 collaboration that validated NeuroXT's MRI-based AI technology, researchers analyze data from patients who have received Alzheimer's treatments at BIDMC for over a year to explore imaging biomarkers for personalized treatment strategies.
• Newcle Science Inc.minorStrategic or Co-development PartnerSigned global clinical collaboration with Newcle Science Inc. in August 2022 for clinical collaboration activities.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Qure.ai: Qure.ai is a radiology AI vendor with multiple FDA clearances across CT and MRI workflows. It is a broad incumbent in clinical imaging AI that competes for hospital PACS-integrated AI budgets.
• RapidAI: RapidAI sells AI-driven imaging analytics (predominantly stroke/neurovascular) to hospitals and clinical trial sponsors. Comparable as a neuro-imaging AI vendor targeting the same hospital and pharma customers.
• Siemens Healthineers (AI-Rad Companion): Siemens Healthineers distributes AI-Rad Companion, an AI platform that includes neuroimaging analytics integrated with hospital MRI scanners. As an installed-base incumbent, it can ship AD biomarker features to large hospital accounts without standalone adoption risk.
• GE HealthCare (Edison Platform): GE HealthCare's Edison AI platform includes brain MRI analytics and integrates across its installed scanner base. Comparable as a large-incumbent AI imaging ecosystem competing for hospital AI budgets.

Direct peers

• icometrix: icometrix (icobrain) develops FDA-cleared AI software that quantifies brain MRI biomarkers for multiple sclerosis, dementia, and traumatic brain injury — directly comparable as a brain MRI AI imaging biomarker platform sold to hospitals and pharma for CNS clinical trials.
• Cortechs.ai: Cortechs.ai markets NeuroQuant, an FDA-cleared MRI brain volumetry solution for neurodegenerative disease quantification. It is a direct competitor in brain MRI AI analytics for neurology practices and pharma imaging cores.

Emerging players

• Subtle Medical: Subtle Medical builds AI for MRI image acquisition and analysis across neurology and oncology. Overlap is partial — it focuses on scan-enhancement rather than AD-specific biomarker extraction but competes for the same AI-imaging-in-neurology budget.
• Avicenna AI: Avicenna AI provides radiology AI workflow and triage tools integrated with PACS. While not neurology-only, it competes in the broader hospital AI imaging buying cycle that NeuroXT must win into.
• Cerveau Technologies: Cerveau licenses tau PET imaging biomarkers (including flortaucipir) to pharma for Alzheimer's clinical trials. It competes with NeuroXT's NEXT-STAGE for pharma AD trial biomarker budgets, though on the PET rather than MRI side.
• BrainBox Solutions: BrainBox Solutions develops AI-based MRI biomarkers for neurological injury (e.g., concussion/traumatic brain injury). It overlaps as a brain-MRI biomarker AI startup pursuing pharma and clinical validation partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroXT